Guanabenz

Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist that is selective to the alpha-2 adrenergic receptor. Guanabenz is used as an antihypertensive drug, i.e. to treat high blood pressure (hypertension).[1][2]

Guanabenz
Clinical data
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa686003
ATC code
  • none
Pharmacokinetic data
Protein binding90%
Elimination half-life6 hours
Identifiers
  • 2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.023.410
Chemical and physical data
FormulaC8H8Cl2N4
Molar mass231.08 g·mol−1
3D model (JSmol)
  • Clc1cccc(Cl)c1\C=N\N=C(/N)N
  • InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ checkY
  • Key:WDZVGELJXXEGPV-YIXHJXPBSA-N checkY
  (verify)

The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness.[3]

Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.

Other possible uses

Guanabenz also has some anti-inflammatory properties in different pathological situations, including multiple sclerosis.[4]

Guanabenz was found in one study to exert an inhibitory effect by decreasing the abundance of the enzyme CH25H, a cholesterol hydroxylase linked to antiviral immunity. Therefore, it is suggested that the drug and similar compounds could be used to treat type I interferon-dependent pathologies and that the CH25H enzyme could be a therapeutic target to control these diseases,[5] including amyotrophic lateral sclerosis.

See also

References
  1. Walker BR, Hare LE, Deitch MW (1982). "Comparative antihypertensive effects of guanabenz and clonidine". The Journal of International Medical Research. 10 (1): 6–14. doi:10.1177/030006058201000102. PMID 7037502. S2CID 2139809.
  2. Bonham AC, Trapani AJ, Portis LR, Brody MJ (1984). "Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine". Journal of Hypertension Supplement. 2 (3): S543-6. PMID 6599714.
  3. "Guanabenz | The Merck Index Online". www.rsc.org. Retrieved 2023-04-17.
  4. Way, Sharon W.; Podojil, Joseph R.; Clayton, Benjamin L.; Zaremba, Anita; Collins, Tassie L.; Kunjamma, Rejani B.; Robinson, Andrew P.; Brugarolas, Pedro; Miller, Robert H.; Miller, Stephen D.; Popkoa, Brian (March 13, 2015). "Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic". Nature Communications. 6 (1): 6532. doi:10.1038/ncomms7532. PMC 4360920. PMID 25766071.
  5. Perego, Jessica; Mendes, Andreia; Bourbon, Clarisse; Camosseto, Voahirana; Combes, Alexis; Liu, Hong; Manh, Thien-Phong Vu; Dalet, Alexandre; Chasson, Lionel; Spinelli, Lionel; Bardin, Nathalie; Chiche, Laurent; Santos, Manuel A. S.; Gatti, Evelina; Pierre, Philippe (2018-01-23). "Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2α dephosphorylation by the GADD34/PP1c complex". Science Signaling. 11 (514): eaam8104. doi:10.1126/scisignal.aam8104. ISSN 1945-0877.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.